$0.03
6.65% yesterday
Nasdaq, Nov 25, 09:32 pm CET
ISIN
US89237H1005
Symbol
TCON
Sector
Industry

TRACON Pharmaceuticals, Inc. Stock price

$0.03
-0.04 57.18% 1M
-1.46 98.02% 6M
-3.47 99.16% YTD
-3.64 99.20% 1Y
-56.17 99.95% 3Y
-70.90 99.96% 5Y
-1,879.97 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 6.65%
ISIN
US89237H1005
Symbol
TCON
Sector
Industry

Key metrics

Market capitalization $100.00k
Enterprise Value $-6.17m
P/E (TTM) P/E ratio 0.01
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -1.93
P/S ratio (TTM) P/S ratio 0.03
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -64.44%
Revenue (TTM) Revenue $3.20m
EBIT (operating result TTM) EBIT $-9.31m
Free Cash Flow (TTM) Free Cash Flow $9.22m
Cash position $6.27m
EPS (TTM) EPS $3.79
P/E forward negative
P/S forward 16.90
EV/Sales forward negative
Short interest 6.26%
Show more

Is TRACON Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

TRACON Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a TRACON Pharmaceuticals, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a TRACON Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from TRACON Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3.20 3.20
64% 64%
100%
- Direct Costs 0.01 0.01
0% 0%
0%
3.19 3.19
65% 65%
100%
- Selling and Administrative Expenses 5.44 5.44
36% 36%
170%
- Research and Development Expense 7.03 7.03
57% 57%
220%
-9.29 -9.29
42% 42%
-290%
- Depreciation and Amortization 0.01 0.01
0% 0%
0%
EBIT (Operating Income) EBIT -9.31 -9.31
42% 42%
-291%
Net Profit 5.20 5.20
118% 118%
163%

In millions USD.

Don't miss a Thing! We will send you all news about TRACON Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TRACON Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
4 months ago
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.
Neutral
GlobeNewsWire
6 months ago
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy

Company Profile

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Head office United States
CEO Craig Jalbert
Employees 17
Founded 2004
Website www.traconpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today